The hidden link between kidney stone disease and obesity
February 28, 2025 / Obesity / Kidney Stones / Metabolic Health / Fatty Liver Disease
Obesity significantly increases kidney stone risk, particularly calcium oxalate and uric acid stones, due to metabolic imbalances. Research links fatty liver disease (MASLD) to oxalate production, highlighting the need for obesity management in kidney stone prevention through lifestyle and medical interventions.
Do sugar substitutes really help? New research reveals their impact on metabolism and gut health
February 27, 2025 / Artificial Sweeteners / Metabolism / Gut Health / Weight Loss / Diabetes
Low- and no-calorie sweeteners (LNCSs) help reduce sugar intake but may impact metabolism, insulin response, and gut microbiome health. While generally considered safe, ongoing research explores their long-term effects, highlighting the need for balanced consumption and further regulatory oversight.
Mediterranean diet could help lower cancer risk in obesity
March 2, 2025 / Mediterranean Diet / Cancer Risk / Obesity / Cancer Prevention
A Mediterranean diet lowers obesity-related cancer risk by 6%, independent of BMI. Benefits include reduced colorectal, liver, and kidney cancer risks. Future research aims to explore mechanisms, including inflammation and gut microbiota, supporting dietary counseling as a preventive strategy.
The Brain Plays a Central Role in the Development of Obesity
March 3, 2025 / Insulin Resistance / Obesity / Brain Function / Weight Gain / Type 2 Diabetes
Short-term consumption of processed, high-calorie foods reduces brain insulin sensitivity, potentially triggering obesity and type 2 diabetes. This effect persists even after resuming a normal diet, highlighting the brain’s critical role in metabolic regulation and obesity development.
How rethinking obesity could reshape life underwriting – Swiss Re
February 27, 2024 / Obesity / Life Insurance Underwriting / BMI Alternative / Risk Assessment / Metabolic Health
Swiss Re supports redefining obesity in life underwriting by incorporating metabolic health markers alongside BMI. This shift could improve risk assessment accuracy, impact premiums, and encourage healthier lifestyles, aligning with evolving research on obesity’s metabolic effects beyond weight alone.
Lifesaving drug successfully lowers cholesterol levels and body weight
March 2, 2025 / Nanogel Drug / Obesity / Targeted Cholesterol Treatment / Weight Loss / Thyroid Hormone / Metabolic Disorder Therapy
Nanogel-delivered thyromimetic drugs selectively target the liver, reducing cholesterol, inflammation, and obesity-related weight gain without harmful side effects. This breakthrough offers a promising, precise metabolic treatment for obesity and related disorders, potentially revolutionizing cholesterol and weight management.
Prize for excellence awarded to clinical researcher for distinguished and innovative studies in obesity and its complications
February 27, 2025 / Obesity Research / Mitochondria / Obesity Metabolism / EASO Novo Nordisk / Clinical Obesity Research Advancements
Professor Kirsi Pietiläinen received the 2025 EASO–Novo Nordisk Foundation Obesity Prize for Excellence for her research on obesity’s metabolic effects, particularly mitochondrial dysfunction in fat tissue. Her work advances obesity treatment strategies, including metabolic interventions and weight-loss mechanisms.
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
February 25, 2025 / RNAi Therapy / Obesity / Weight Loss / Preclinical Results / Tirzepatide
Arrowhead’s RNAi therapy, ARO-ALK7, targets adipose tissue to reduce fat mass while preserving lean mass. Preclinical studies show enhanced weight loss and metabolic benefits, especially when combined with tirzepatide, offering a novel approach to obesity treatment with promising clinical potential.
Missing protein keeps mice slim on high-fat diet
February 26, 2025 / CD44 Protein / Obesity / Obesity Treatment / Metabolic Health
CD44 deficiency prevents obesity in mice on a high-fat diet by suppressing fat cell formation via reduced serotonin levels. This novel mechanism highlights CD44 as a potential therapeutic target, offering a complementary approach to existing obesity treatments like GLP-1 receptor agonists.
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
February 25, 2024 / AMPK Activator / Drug Development / Nimbus Lilly / Cardiometabolic Collaboration / Drug Discovery
Nimbus Therapeutics, in collaboration with Eli Lilly, achieved a preclinical milestone in developing a selective AMPK isoform activator for cardiometabolic diseases. This breakthrough could lead to new treatments for obesity, metabolic disorders, and cardiovascular conditions.
Bioinformatic analysis of molecular expression patterns during the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD)
March 1, 2025 / MASLD Biomarker Discovery / Gene Expression / Liver Disease / Metabolic Liver Disease
Bioinformatic analysis identified key gene expression patterns linked to MASLD progression, highlighting CYP7A1 and TNFRSF12A as potential biomarkers for hepatocellular carcinoma risk. These findings may improve early diagnosis, risk prediction, and targeted therapies for MASLD and related liver diseases.
Review sheds light on the mechanistic role of long non-coding RNAs in liver disease
February 28, 2025 / IncRNAs / Liver Disease / MASLD / Liver Fibrosis / RNA Therapy
Long non-coding RNAs (lncRNAs) regulate liver metabolism, inflammation, and fibrosis in MASLD. Targeting pathogenic or protective lncRNAs may offer new therapeutic strategies, but challenges like species specificity and delivery mechanisms require further research for clinical translation.
Impaired mitochondrial degradation of CHCHD2 promotes metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma by upregulating VEGFA
March 1, 2025 / CHCHD2 / Liver Cancer / MASH-related Hepatocellular Carcinoma
Impaired mitochondrial degradation of CHCHD2 in MASH promotes hepatocellular carcinoma by upregulating VEGFA, enhancing tumor-supporting angiogenesis. Targeting CHCHD2 or restoring mitochondrial protease ClpXP function may offer novel therapeutic strategies for MASH-associated liver cancer.
Lilly’s appetite for deals in IBD space provides lifeline for Organovo
February 25, 2025 / Eli Elly / MASH Treatment / Metabolic Disease Therapy / Trizepatide
Eli Lilly acquired Organovo’s FXR314, an oral FXR agonist for MASH and IBD, strengthening its metabolic and inflammatory disease pipeline. FXR314 shows promise in combination therapy, potentially complementing GLP-1/GIP agonists like tirzepatide for MASH and obesity treatment.
Eli Lilly buys Organovo’s FXR program for $10M, sending biotech’s stock skyrocketing 244%
February 26, 2025 / Eli Lilly / Liver Disease / Metabolic Disease / Fibrosis Therapy
Eli Lilly acquired Organovo’s FXR314, an oral FXR agonist for inflammatory bowel disease and metabolic diseases, in a $10M deal with milestone potential. FXR314, phase 2-ready for liver fibrosis, offers promise despite past FXR agonist setbacks in MASH treatment.
Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications
March 3, 2025 / Hepatocellular Carcinoma Metabolism / Metabolic Reporgramming / Liver Cancer / Fatty Acid Metabolism
Hepatocellular carcinoma undergoes metabolic reprogramming, altering glycolysis, amino acid, and fatty acid metabolism. These changes promote tumor growth and therapy resistance. Targeting metabolic vulnerabilities, such as acetyl-CoA metabolism and oxidative stress pathways, may offer new therapeutic strategies for HCC treatment.
Increased odds of metabolic syndrome among adults with depressive symptoms or antidepressant use
February 27, 2025 / Depression / Metabolic Syndrome / Mental Health / Insulin Resistance
Depressive symptoms and antidepressant use, particularly tricyclic antidepressants, are associated with increased odds of metabolic syndrome (MetS). While antidepressant duration was not a significant factor, these findings highlight the need to monitor metabolic health in patients with depression.
Cardiovascular death risk increases with cardiovascular-kidney-metabolic syndrome stage
March 3, 2024 / CKM Syndrome / Cardiovascular Risk / Cardiovascular-kidney-metabolic Syndrome / Heart Disease
Cardiovascular mortality risk increases with advancing cardiovascular-kidney-metabolic (CKM) syndrome stages. Stage 4 significantly reduces survival time, while stage 1 offers a key window for early intervention. CKM staging may improve risk stratification and optimize cardioprotective treatment strategies.